Single-Cell Transcriptomic Identification of Drug Repurposing Candidates for Endometriosis via Endometrial Biopsy scRNA-seq

Glen Charles Ritschel, Claude
2026 · doi:10.5281/zenodo.19412623 · W7149412234
preprint OA: green CC0
🔓 Open OA copy Full text JSON View on OpenAlex View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-07-17 ⓘ

Single-cell RNA sequencing of endometrial biopsies identified 20,510 potential drug repurposing candidates for endometriosis, with CHEMBL5653589 emerging as a top candidate affecting stromal fibroblast activation.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by qwen3.7-flash, 2026-09-11 · read from full text ⓘ

This computational study utilized single-cell RNA sequencing data from 47,957 endometrial biopsy cells to identify drug repurposing candidates for endometriosis. The analysis resolved 31 cell clusters and highlighted a stromal fibroblast activation signature through differential expression between endometriosis and control samples. Researchers screened druggable targets against the ChEMBL database, identifying top compounds such as CHEMBL5653589 and Lestaurltinib based on multi-target scoring metrics. This paper is centrally about endometriosis — specifically the identification of potential therapeutic agents via single-cell transcriptomic profiling of endometrial biopsies.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

A computational drug repurposing study of human endometriosis using single-cell RNA sequencing data (GSE179640, 47,957 endometrial biopsy cells, 29 endometriosis / 3 control samples). scVI batch correction resolved 31 Leiden clusters annotated as 10 cell types including stromal fibroblasts, endometrial epithelial cells, macrophages, NK cells, T cells, mast cells, smooth muscle, endothelial, B cells, and plasma cells. Wilcoxon differential expression (Endo vs Control) identified 500 significant genes dominated by a stromal fibroblast activation signature (COL1A1, FN1, SPARC, TAGLN). ChEMBL screening (pChEMBL≥6.0) across 184 druggable targets yielded 20,510 scored compounds; 20,117 confirmed novel via PubChem. Top candidates: CHEMBL5653589 (190.34, 18 targets), LESTAURTINIB (168.64, 16 targets), CHEMBL3752910 (118.90, 11 targets). Seven cross-disease watchlist compounds confirmed. CHEMBL5653589 ranks #1 across 8 independent Ritschel Research disease pipelines. Authors: Glen Charles Ritschel (Ritschel Research, Tega Cay SC) and Claude (Anthropic, San Francisco CA).
Full text 1,398 characters · extracted from oa-doi-fallback · click to expand
Single-Cell Transcriptomic Identification of Drug Repurposing Candidates for Endometriosis via Endometrial Biopsy scRNA-seq Authors/Creators - 1. Ritschel Research - 2. Anthropic Description A computational drug repurposing study of human endometriosis using single-cell RNA sequencing data (GSE179640, 47,957 endometrial biopsy cells, 29 endometriosis / 3 control samples). scVI batch correction resolved 31 Leiden clusters annotated as 10 cell types including stromal fibroblasts, endometrial epithelial cells, macrophages, NK cells, T cells, mast cells, smooth muscle, endothelial, B cells, and plasma cells. Wilcoxon differential expression (Endo vs Control) identified 500 significant genes dominated by a stromal fibroblast activation signature (COL1A1, FN1, SPARC, TAGLN). ChEMBL screening (pChEMBL≥6.0) across 184 druggable targets yielded 20,510 scored compounds; 20,117 confirmed novel via PubChem. Top candidates: CHEMBL5653589 (190.34, 18 targets), LESTAURTINIB (168.64, 16 targets), CHEMBL3752910 (118.90, 11 targets). Seven cross-disease watchlist compounds confirmed. CHEMBL5653589 ranks #1 across 8 independent Ritschel Research disease pipelines. Authors: Glen Charles Ritschel (Ritschel Research, Tega Cay SC) and Claude (Anthropic, San Francisco CA). Files Files (14.5 kB) | Name | Size | Download all | |---|---|---| | md5:56ca46f0e52046ee9525a5c8f2e32b17 | 14.5 kB | Download |

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosis

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2026) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.

Source provenance

openalex
last seen: 2026-07-04T06:01:59.113452+00:00
License: CC0 · commercial use OK